Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Video library· Cell Biology & Drug Development

IGF-1 Signaling: A Key Pathway in Cancer, Longevity & Drug Development

Thumbnail from YouTube. Playing loads the YouTube player.

History & recommendationsOff

Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.

Up to 120 items · 90 days. Turning this off deletes the history.
Open saved items & history →

About this video

Creator description · original language

The content of this video is based on Xu Y, Wei J, Wang W, Mao Z, Wang D, Zhang T, Zhang P. Oleanolic Acid Slows Down Aging Through IGF-1 Affecting the PI3K/AKT/mTOR Signaling Pathway. Molecules. 2025 Feb 6;30(3):740. doi: 10.3390/molecules30030740. PMID: 39942843; PMCID: PMC11820160. The IGF-1 signaling pathway plays a crucial role in cell proliferation, longevity, and DNA repair, making it a key target for cancer therapy and anti-aging research. In this video, we break down how IGF-1 activates the PI3K-AKT-mTOR pathway, driving DNA replication and cell growth. We also explore how targeted therapies, such as IGF-1R and mTOR inhibitors, are being developed to suppress tumor growth and enhance longevity. Understanding this pathway opens new doors for precision medicine in cancer, aging-related disorders, and metabolic diseases. Watch now to learn more!

Cell Biology & Drug Development · 2 min · Source published: 2025-02-15

Added to Harbor: 10/22/2026

Original on YouTube ↗

Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…